physostigmine heptyl has been researched along with tacrine in 16 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 8 (50.00) | 18.2507 |
| 2000's | 6 (37.50) | 29.6817 |
| 2010's | 2 (12.50) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, YL; Dunaiskis, A; Hedberg, K; Ives, J; Johnson, J; Jones, S; Liston, D; Nielsen, J; Russo, L | 1 |
| Brossi, A; Greig, NH; Holloway, HW; Whittaker, NF; Yu, QS; Zhu, X | 1 |
| Alley, GM; Brossi, A; Deschamps, JR; Greig, NH; Holloway, HW; Kulkarni, SS; Lahiri, DK; Luo, W; Parrish, D; Yu, QS; Zhan, M | 1 |
| Brossi, A; Greig, NH; Holloway, HW; Kulkarni, SS; Lahiri, DK; Luo, W; Parrish, DA; Shafferman, A; Tweedie, D; Yu, QS | 1 |
| Chaudhaery, SS; Nath, C; Nazir, A; Roy, KK; Sammi, SR; Saxena, AK; Saxena, G; Shakya, N | 1 |
| Boido, V; Carotti, A; Catto, M; Giangreco, I; Nicolotti, O; Novelli, F; Pisani, L; Sparatore, A; Sparatore, F; Tasso, B; Tonelli, M | 1 |
| Giacobini, E; Messamore, E; Ogane, N; Warpman, U | 1 |
| Cutler, NR; Sramek, JJ | 2 |
| Camacho, F; Smith, CP; Vargas, HM; Winslow, JT | 1 |
| Braida, D; Griffini, P; Lamperti, M; Maggi, A; Paladini, E; Sala, M | 1 |
| Cross, AJ; De Souza, RJ; Green, AR; Misra, A; Murray, TK; Snape, MF; Williams, JL | 1 |
| Kása, P; Rakonczay, Z; Török, L | 1 |
| Braida, D; Ottonello, F; Sala, M; Virag, W | 1 |
| Rakonczay, Z | 1 |
| Chapin, D; Hubbard, ST; Jones, SB; Liston, DR; Nason, D; Nielsen, JA; Ramirez, A; Shalaby, IA; Villalobos, A; White, WF | 1 |
1 trial(s) available for physostigmine heptyl and tacrine
| Article | Year |
|---|---|
The target population in phase I clinical trials of cholinergic compounds in Alzheimer disease: the role of the "bridging study".
Topics: Alzheimer Disease; Cholinergic Agents; Cholinesterase Inhibitors; Dose-Response Relationship, Drug; Drug Tolerance; Humans; Physostigmine; Safety; Tacrine | 1995 |
15 other study(ies) available for physostigmine heptyl and tacrine
| Article | Year |
|---|---|
Syntheses, resolution, and structure-activity relationships of potent acetylcholinesterase inhibitors: 8-carbaphysostigmine analogues.
Topics: Animals; Brain; Cholinesterase Inhibitors; Lethal Dose 50; Male; Mice; Physostigmine; Structure-Activity Relationship | 1992 |
Anticholinesterase activity of compounds related to geneserine tautomers. N-Oxides and 1,2-oxazines.
Topics: Acetylcholinesterase; Alkaloids; Butyrylcholinesterase; Cholinesterase Inhibitors; Cyclic N-Oxides; Humans; Isomerism; Oxazines; Structure-Activity Relationship | 2002 |
Novel anticholinesterases based on the molecular skeletons of furobenzofuran and methanobenzodioxepine.
Topics: Acetylcholinesterase; Amyloid beta-Protein Precursor; Benzofurans; Butyrylcholinesterase; Carbamates; Cell Line; Cell Survival; Cholinesterase Inhibitors; Crystallography, X-Ray; Humans; Models, Molecular; Molecular Structure; Neurons; Oxepins; Structure-Activity Relationship | 2005 |
Inhibition of human acetyl- and butyrylcholinesterase by novel carbamates of (-)- and (+)-tetrahydrofurobenzofuran and methanobenzodioxepine.
Topics: Acetophenones; Acetylcholinesterase; Animals; Benzofurans; Butyrylcholinesterase; Carbamates; Cholinesterase Inhibitors; Crystallography, X-Ray; Furans; Heterocyclic Compounds, 3-Ring; Humans; Models, Molecular; Oxepins; Stereoisomerism; Structure-Activity Relationship; Torpedo | 2006 |
Novel carbamates as orally active acetylcholinesterase inhibitors found to improve scopolamine-induced cognition impairment: pharmacophore-based virtual screening, synthesis, and pharmacology.
Topics: Acetylcholinesterase; Administration, Oral; Animals; Avoidance Learning; Caenorhabditis elegans; Carbamates; Catalytic Domain; Cholinesterase Inhibitors; Databases, Factual; Hydrogen Bonding; Hydrophobic and Hydrophilic Interactions; Male; Mice; Models, Molecular; Nootropic Agents; Quantitative Structure-Activity Relationship; Scopolamine | 2010 |
Quinolizidinyl derivatives of bi- and tricyclic systems as potent inhibitors of acetyl- and butyrylcholinesterase with potential in Alzheimer's disease.
Topics: Acetylcholinesterase; Alzheimer Disease; Animals; Butyrylcholinesterase; Cattle; Cholinesterase Inhibitors; Crystallography, X-Ray; Dose-Response Relationship, Drug; Erythrocytes; Models, Molecular; Molecular Structure; Quinolizidines; Stereoisomerism; Structure-Activity Relationship | 2011 |
Cholinesterase inhibitor effects on extracellular acetylcholine in rat cortex.
Topics: Acetylcholine; Animals; Cerebral Cortex; Cholinesterase Inhibitors; Chromatography, High Pressure Liquid; Dialysis; Electrochemistry; Extracellular Space; Male; Physostigmine; Rats; Rats, Sprague-Dawley; Tacrine | 1993 |
Scientific and ethical concerns in clinical trials in Alzheimer's patients: the bridging study.
Topics: Alzheimer Disease; Cholinesterase Inhibitors; Clinical Trials as Topic; Dihydropyridines; Ethics, Medical; Humans; Nootropic Agents; Oximes; Physostigmine; Psychotropic Drugs; Pyridines; Tacrine; Thiadiazoles | 1995 |
Alpha 2-adrenoceptor antagonists potentiate acetylcholinesterase inhibitor effects on passive avoidance learning in the rat.
Topics: Adrenergic alpha-Antagonists; Animals; Avoidance Learning; Benzazepines; Cholinesterase Inhibitors; Drug Synergism; Galantamine; Idazoxan; Male; Physostigmine; Rats; Rats, Sprague-Dawley; Tacrine; Yohimbine | 1996 |
An inverted U-shaped curve for heptylphysostigmine on radial maze performance in rats: comparison with other cholinesterase inhibitors.
Topics: Amnesia; Analysis of Variance; Animals; Behavior, Animal; Cholinesterase Inhibitors; Donepezil; Dose-Response Relationship, Drug; Indans; Male; Maze Learning; Motor Activity; Muscarinic Antagonists; Physostigmine; Piperidines; Rats; Rats, Wistar; Scopolamine; Tacrine | 1996 |
A comparative study in rats of the in vitro and in vivo pharmacology of the acetylcholinesterase inhibitors tacrine, donepezil and NXX-066.
Topics: Acetylcholinesterase; Animals; Butyrylcholinesterase; Carbachol; Cholinesterase Inhibitors; Donepezil; Drug Evaluation, Preclinical; Humans; Indans; Indoles; Injections, Intraperitoneal; Isoquinolines; Logistic Models; Male; Physostigmine; Piperidines; Rats; Structure-Activity Relationship; Tacrine; Tumor Cells, Cultured | 1999 |
Preferential inhibition of acetylcholinesterase molecular forms in normal human brain.
Topics: Acetylcholinesterase; Benzazepines; Brain; Cholinesterase Inhibitors; Humans; Physostigmine; Tacrine | 1999 |
Excitatory and inhibitory effects of second-generation cholinesterase inhibitors on rat gastrointestinal transit.
Topics: Administration, Oral; Animals; Cholinesterase Inhibitors; Donepezil; Dose-Response Relationship, Drug; Gastrointestinal Transit; Hydrocarbons, Brominated; Indans; Male; Physostigmine; Piperidines; Pirenzepine; Rats; Rats, Wistar; Receptor, Muscarinic M1; Receptors, Muscarinic; Receptors, Nicotinic; Scopolamine; Tacrine | 2000 |
Potencies and selectivities of inhibitors of acetylcholinesterase and its molecular forms in normal and Alzheimer's disease brain.
Topics: Acetylcholinesterase; Alzheimer Disease; Benzazepines; Brain; Butyrylcholinesterase; Carbamates; Cerebral Cortex; Cholinesterase Inhibitors; Edrophonium; Humans; In Vitro Techniques; Phenylcarbamates; Physostigmine; Rivastigmine; Tacrine; Trichlorfon | 2003 |
Pharmacology of selective acetylcholinesterase inhibitors: implications for use in Alzheimer's disease.
Topics: Acetylcholine; Alzheimer Disease; Animals; Brain; Butyrylcholinesterase; Cholinesterase Inhibitors; Donepezil; Dose-Response Relationship, Drug; Humans; Indans; Male; Mice; Physostigmine; Piperidines; Rats; Rats, Sprague-Dawley; Tacrine | 2004 |